Price
$234.32
Increased by +1.40%
Dollar volume (20D)
297.00 M
ADR%
1.97
Earnings report date
Aug 1, 2024
Shares float
288.34 M
Shares short
2.32 M [0.80%]
Shares outstanding
289.01 M
Market cap
66.79 B
Beta
0.44
Price/earnings
49.48
20D range
218.75 237.71
50D range
218.75 242.26
200D range
218.75 266.29

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.

The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems.

The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers.

The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products.

The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
May 14, 24 3.17
Increased by +10.84%
2.97
Increased by +6.73%
Mar 13, 24 2.68
Decreased by -10.07%
2.40
Increased by +11.67%
Nov 9, 23 3.42
Increased by +24.36%
3.43
Decreased by -0.29%
Aug 3, 23 2.96
Increased by +11.28%
2.91
Increased by +1.72%
May 4, 23 2.86
Decreased by -10.06%
2.74
Increased by +4.38%
Feb 2, 23 2.98
Decreased by -18.13%
2.68
Increased by +11.19%
Nov 10, 22 2.75
Increased by +6.18%
2.74
Increased by +0.36%
Aug 4, 22 2.66
Decreased by -2.92%
2.50
Increased by +6.40%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 24 5.04 B
Increased by +4.65%
537.00 M
Increased by +16.74%
Increased by +10.64%
Increased by +11.56%
Dec 31, 23 4.71 B
Increased by +2.62%
281.00 M
Decreased by -44.79%
Increased by +5.97%
Decreased by -46.20%
Sep 30, 23 5.09 B
Increased by +6.85%
108.00 M
Decreased by -62.37%
Increased by +2.12%
Decreased by -64.78%
Jun 30, 23 4.88 B
Increased by +5.11%
407.00 M
Increased by +13.06%
Increased by +8.34%
Increased by +7.56%
Mar 31, 23 4.82 B
Decreased by -3.79%
460.00 M
Increased by +1.32%
Increased by +9.54%
Increased by +5.31%
Dec 31, 22 4.59 B
Decreased by -2.80%
509.00 M
Decreased by -24.82%
Increased by +11.10%
Decreased by -22.65%
Sep 30, 22 4.76 B
Decreased by -7.28%
287.00 M
Increased by +8.30%
Increased by +6.03%
Increased by +16.81%
Jun 30, 22 4.64 B
Decreased by -5.09%
360.00 M
Decreased by -31.43%
Increased by +7.76%
Decreased by -27.75%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY